PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

First Patient Treated with LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance - Collaboration brings new tools to interventional radiologists and oncologists to help treat liver cancer and enhanced patient care - LCBeadLUMI.com / BTG-IM.com
First Patient Treated with LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

 

NewswireToday - /newswire/ - London, United Kingdom, 2016/02/03 - Collaboration brings new tools to interventional radiologists and oncologists to help treat liver cancer and enhanced patient care - LCBeadLUMI.com / BTG-IM.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, a global specialist healthcare company, and Royal Philips (NYSE: PHG; AEX: PHIA), announced today a significant milestone in their collaboration with the treatment of the first liver cancer patient with LC Bead LUMI™ in conjunction with Philips Live Image Guidance, targeting a hypervascular tumor with the goal to block blood flow to achieve tumor necrosis.

Liver cancer is the second leading cause of cancer deaths in the world1, and one of the most challenging to treat. Each year, more than 700,000 patients worldwide are diagnosed with liver cancer.2 Interventional embolization is an option for some patients with tumors that cannot be removed by surgery.

The first patient treated signals the next stage in commercializing next generation embolic beads, which can be visualized during interventional procedures, allowing enhanced visualization to evaluate completeness of tumor treatment. As a result of the collaboration between BTG and Philips, for the first time doctors will be able to see rather than assume the location of the LC Bead LUMI™, in order to deliver their treatment with more confidence when treating liver cancer.

“The aim with this new radiopaque embolic bead and visualization technology is to provide clinicians like me the ability to make real-time adjustments while conducting the embolization procedure, so that we can optimize patient’s treatment and hopefully improve targeting accuracy,” said Bradford Wood, M.D., Director of the NIH Center for Interventional Oncology• and Chief of Interventional Radiology. “It is reassuring for the clinician and the patient to know that the treatment was delivered exactly where it was aimed, and where it was needed. Treating the first patient using LC Bead LUMI™ in combination with dedicated Philips 2D X-ray and 3D CBCT image guidance is a milestone in our public-private partnership with both of our industry research partners. The imaging of the beads during this first procedure was exquisite and provided valuable information.”

By enabling visualization of beads during an embolization procedure, LC Bead LUMI™ will help embolization technology achieve its full potential. LC Bead LUMI™ has been developed with revolutionary radiopacity technology in collaboration with Philips that enables real-time visualization of bead location during embolization. LC Bead LUMI™, supported by Philips Live Image Guidance, has the potential to offer interventional radiologists more control, allowing enhanced visualization to evaluate the completeness of tumor treatment and end-point determination.

“BTG continues to advance its leadership in Interventional Medicine by actively listening to our customers and providing creative solutions to meet their clinical needs,” said Peter Pattison, Interventional Oncology General Manager, BTG. “Several years ago, we began scientific collaboration with Philips to evaluate the benefits of better image-guided therapy and this venture resulted in the ability to calibrate Philips’ imaging software to LC Bead LUMI™. The clinical impact of the BTG / Philips collaboration is now helping interventional radiologists and multi-disciplinary teams make enhanced treatment decisions for patients with liver cancer.”

Ronald Tabaksblat, Business Leader, Imaging Guided Therapy Systems, Philips commented “Minimally-invasive therapy procedures provide key benefits for healthcare systems and patients, and intelligent image guidance is an essential part of these procedures. We aim to continuously improve Image Guided Therapy and our collaboration with BTG to provide enhanced visibility and guidance during interventional embolization procedures is another important milestone in this exciting journey to help deliver excellent treatment and enhanced patient care.”

LC Bead LUMI™ was cleared for clinical use in the US in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead®.

BTG and Philips will showcase their advancements in interventional oncology at the upcoming symposium on Clinical Interventional Oncology (CIO), taking place Feb. 6 7 in Hollywood, FL. For information on BTG, visit btg-im.com, and to learn more about Philips integrated solutions for diagnostics and therapeutic oncology, please visit philips.com/io.

*NIH does not endorse or recommend any commercial products, processes, or services. The views and opinions of authors expressed here do not necessarily state or reflect those of the US Government or the NIH, and they may not be used for advertising or product endorsement purposes.

About LC Bead LUMI™
LC Bead LUMI™ (LCBeadLUMI.com) is the first commercially available radiopaque embolic bead cleared by the US Food & Drug Administration (FDA) for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead LUMI™ provides visible confirmation of bead location during AVM procedure. The lasting radiopacity of LC Bead LUMI™ means they will also be visible in follow-up scans.

About BTG Interventional Medicine
BTG Interventional Medicine (btg-im.com) is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

About Royal Philips
Royal Philips (philips.com) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately 104,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

Contacts

Royal Philips: Kathy O’Reilly, Philips Group Communications
P: +1 978-659-2638 / M: +1 978-221-8919
E: kathy.oreilly[.]philips.com.

Media Liaison: Jonathan Falcone
P: +44(0)20 8618 2752 / M: +44(0)78 2523 8898
El: j.falcone[.]togorun.com

Media Liaison US: Banks Willis
P: +1 202-828-5073 / M: +1 202-577-5847
E: b.willis[.]togorun.com.

References:
1. World Health Organization (WHO). Cancer factsheet. Last accessed January 25, 2016.
2. American Cancer Society. What are the key statistics about liver cancer?. Last accessed January 25, 2016.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


First Patient Treated with LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG Interventional Med. | LC Bead LUMI™
Publisher Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)7773 251178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)